RSV prevention drug shows promise in first year of use
NCT ID NCT07177508
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at how a new medicine called nirsevimab affected RSV infections and hospital stays in children under 2 years old in the Australian Capital Territory. Researchers used routine health data from over 2,300 kids to compare RSV cases and emergency visits before and after the medicine was introduced. The goal was to see if nirsevimab helped reduce the burden of RSV in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nirsevimab
- What this could lead to
- If successful, this study could show that nirsevimab reduces RSV-related hospital visits in young children, supporting its wider use for prevention.
- What could go wrong
- This is an observational study, not a controlled trial, so it can't prove cause and effect. Results may be influenced by other factors like changes in virus spread or healthcare use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRAL (RSV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Canberra Hospital
Garran, Australian Capital Territory, 2605, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.